Dry powder inhaler and system for drug delivery
View Patent ↗A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
1. A method of treatment using a dry powder medicament to be delivered to the pulmonary tract with a dry powder inhalation system, comprising:
opening a dry powder inhaler having a mouthpiece;
loading a cartridge comprising a pre-metered dose of a dry powder medicament in a containment configuration;
closing the inhaler to reconfigure the cartridge to a dosing configuration, wherein in the dosing configuration the inhaler is configured to have at least two inlet apertures, wherein a first inlet aperture is in communication with a first air flow pathway and a second inlet aperture is in communication with a second air flow pathway, and the first airflow pathway and the second airflow pathway converge in a substantially perpendicular manner during an inhalation maneuver; and
inhaling once through the mouthpiece to deliver the dry powder medicament in a single inhalation.
2. The method of claim 1 wherein the dry powder medicament comprises an active agent.
3. The method of claim 2 wherein the active agent comprises at least one of a synthetic organic compound, a protein, a peptide, a sugar, a lipid, an inorganic compound, or a nucleic acid sequence.
4. The method of claim 1 wherein the dry powder medicament comprises a microparticle.
5. The method of claim 4 wherein the microparticle comprises a diketopiperazine.
6. The method of claim 5 wherein the diketopiperazine has the formula 3,6-di(4-X-aminobutyl)-2,5-diketopiperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl.
7. The method of claim 6 wherein the diketopiperazine is 3,6-di(4-fumaryl-aminobutyl)-2,5-diketopiperazine.
8. The method of claim 5 wherein the microparticle comprises an active agent.
9. The method of claim 8 wherein the active agent comprises as least one of a hormone, an anticoagulant, an immunomodulating agent, a vaccine, a cytotoxic agent, an antibiotic, a vasoactive agent, a neuroactive agent, an anesthetic, a sedative, a steroid, a decongestant, an antiviral, an antisense molecule, an antigen, or an antibody or fragment thereof.
10. The method of claim 8 wherein the active agent comprises as least one of insulin or an analog thereof, GLP-1 or an analog thereof, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone and active fragments thereof, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor (GM-CSF), lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, β-galactosidase, exendin, vasoactive intestinal peptide, and argatroban.
11. The method of claim 10 wherein the active agent comprises insulin or an analog thereof.
12. The method of claim 10 wherein the active agent comprises GLP-1 or an analog thereof.
13. A method of de-agglomerating a powder medicament in a dry powder inhalation system, comprising:
providing the dry powder medicament in a container having an internal volume to a dry powder inhaler configured to have at least two inlet apertures, wherein a first inlet aperture is in communication with a first air flow pathway and a second inlet aperture is in communication with a second air flow pathway, and the first airflow pathway and the second airflow pathway converge in a substantially perpendicular manner during an inhalation maneuver, wherein closing said inhaler reconfigures said inhaler into a dosing configuration;
allowing a flow to enter said container which is configured to direct a flow to lift, entrain and circulate the dry powder medicament until the powder medicament comprises individual particles and particle aggregates sufficiently small to pass through one or more dispensing apertures into a mouthpiece.
14. The method of claim 13 , further comprising the step of accelerating the powder particles and/or particle aggregates entrained in the flow leaving the one or more dispensing apertures and entering the mouthpiece.
15. The method of claim 13 wherein the dry powder medicament comprises an active agent.
16. The method of claim 15 wherein the active agent comprises at least one of a synthetic organic compound, a protein, a peptide, a sugar, a lipid, an inorganic compound, or a nucleic acid sequence.
17. The method of claim 16 wherein the dry powder medicament comprises a microparticle.
18. The method of claim 17 wherein the microparticle comprises a diketopiperazine.
19. The method of claim 18 wherein the diketopiperazine has the formula 3,6-di(4-X-aminobutyl)-2,5-diketopiperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl.
20. The method of claim 19 wherein the active agent comprises insulin or an analog thereof.
21. The method of claim 20 wherein the diketopiperazine is 3,6-di(4-fumaryl-aminobutyl)-2,5-diketopiperazine.